SEC Form 4 · accession 0001813798-26-000015
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jim Wassil
Officer — CHIEF OPERATING OFFICER
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 4:59 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 3, 2026 | M | 2,250 | $5.35 | A | 159,791 | D | |
| Common StockF3 | Aug 3, 2026 | S | 861 | $53.502 | D | 158,930 | D | |
| Common StockF4 | Aug 3, 2026 | S | 1,389 | $54.089 | D | 157,541 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $5.35 | Aug 3, 2026 | M | 2,250 | D | — | Apr 17, 2030 | Common Stock | 2,250 | 68,898 | D |
Explanation of responses
- F1Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.
- F2The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
- F3The price reported is a weighted-average price. The shares were sold at prices ranging from $52.915 to $53.91. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The price reported is a weighted-average price. The shares were sold at prices ranging from $53.935 to $54.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5Stock Option is fully vested and exercisable.